# BioNTech Shares Fall 6% After BNT113 Trial Misses Key Endpoint

By Enna Lee

Canonical URL: https://www.tokenpost.com/news/investing/31293
Published: 2026-10-13T15:48:39.000Z
Updated: 2026-10-13T15:48:39.000Z
Section: Investing

> The Phase 2/3 trial did not meet one of its dual primary endpoints, progression-free survival.

BioNTech shares fell about 6% in Tuesday trading after a Phase 2/3 trial of its BNT113 cancer therapy failed to meet one of its dual primary endpoints.

The missed endpoint was progression-free survival.